Harpoon Therapeutics Inc

NASDAQ:HARP  
19.17
-0.63 (-3.18%)
Products, Regulatory

Harpoon Reports Clinical Progress Across All Four TriTAC Pipeline Development Programs

Published: 12/08/2020 14:01 GMT
Harpoon Therapeutics Inc (HARP) - Harpoon Therapeutics - Hpn424 Shown Partial Response in Treatment of Metastatic Castration-resistant Prostate Cancer in Highest Fixed Dose Cohort.
Harpoon Therapeutics Inc - Three of Seven Patients in Highest Fixed Dose Hpn424 Cohort Have Shown Psa Reduction.
Harpoon Therapeutics Inc - Dose Escalation Trials Advancing for Hpn536 and Hpn217.
Harpoon Therapeutics Inc - Initial Data Readouts and Initiation of Expansion Hpn536 and Hpn217 Cohorts Expected in 2021.